Mobile

A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer. ----------------------------...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001751-21

A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer. ---------------------------------------------------------------------------------------------------- Ensayo aleatorizado de fase 1b/2 de AMG 102 o AMG 479 en combinación con panitumumab frente a panitumumab en monoterapia en sujetos con cáncer colorrectal metastásico con KRAS no mutado

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part 1: To identify a tolerable dose of AMG 102 in combination with panitumumab based on the incidence of dose-limiting toxicities (DLTs) Part 2: To evaluate the efficacy as assessed by the overall objective response rate (ORR) of AMG 102 (tolerable dose selected from part 1) in combination with panitumumab and AMG 479 in combination with panitumumab versus panitumumab alone

Critère d'inclusion

  • Wild-Type KRAS Metastatic Colorectal Cancer. --------------------------------------------------------- cáncer colorrectal metastásico con KRAS no mutado

Liens